Literature DB >> 9869948

Dose and rate-dependent effects of adenosine on atrial action potential duration in humans.

J Tebbenjohanns1, B Schumacher, D Pfeiffer, W Jung, B Lüderitz.   

Abstract

Adenosine provokes atrial fibrillation (AF) in some patients with paroxysmal supraventricular tachycardia (PSVT). Which patients are more susceptible to develop atrial fibrillation after the administration of adenosine to terminate PSVT is unknown. We prospectively measured atrial action potential duration (APD) at incremental doses of 3, 6, and 12 mg of adenosine at paced cycle lengths (CLs) of 600, 500, and 400 ms in 25 patients. Bolus injection of adenosine decreased APD at 90% repolarization in a dose- and rate-dependent manner. During paced CLs of 600, 500, and 400 ms, decreases of 8%, 13%, and 19% (p < 0.05), respectively, were found after bolus administration of 3 mg of adenosine. After 6 mg of adenosine, the APD shortened by 12%, 19%, (p < 0.05), and 27% (p < 0.01), respectively. After 12 mg of adenosine, the APD shortened by 15%, 27% (p < 0.05), and 38% (p < 0.01), respectively. Transient AF occurred in 4 of 25 (16%) patients, all during paced CLs of 400 ms, and after adenosine 6 mg in one patient and 12 mg in three patients. Adenosine shortens atrial action potential duration in a dose- and rate-dependent manner. Whether patients with faster rates during PSVT and those given higher doses of adenosine are more prone to develop atrial fibrillation remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9869948     DOI: 10.1023/a:1009758501195

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


  26 in total

1.  Adenosine for paroxysmal supraventricular tachycardia: dose ranging and comparison with verapamil. Assessment in placebo-controlled, multicenter trials. The Adenosine for PSVT Study Group.

Authors:  J P DiMarco; W Miles; M Akhtar; S Milstein; A D Sharma; E Platia; B McGovern; M M Scheinman; W C Govier
Journal:  Ann Intern Med       Date:  1990-07-15       Impact factor: 25.391

2.  Value and limitations of adenosine in the diagnosis and treatment of narrow and broad complex tachycardias.

Authors:  A C Rankin; K G Oldroyd; E Chong; A P Rae; S M Cobbe
Journal:  Br Heart J       Date:  1989-09

3.  Adenosine or adenosine triphosphate for supraventricular tachycardias? Comparative double-blind randomized study in patients with spontaneous or inducible arrhythmias.

Authors:  A C Rankin; K G Oldroyd; E Chong; J W Dow; A P Rae; S M Cobbe
Journal:  Am Heart J       Date:  1990-02       Impact factor: 4.749

4.  Atrial fibrillation induced by adenosine triphosphate.

Authors:  B Belhassen; A Pelleg; D Shoshani; S Laniado
Journal:  Am J Cardiol       Date:  1984-05-01       Impact factor: 2.778

Review 5.  Adenosine and the treatment of supraventricular tachycardia.

Authors:  A C Rankin; R Brooks; J N Ruskin; B A McGovern
Journal:  Am J Med       Date:  1992-06       Impact factor: 4.965

6.  Effect of adenosine on atrioventricular conduction. I: Site and characterization of adenosine action in the guinea pig atrioventricular node.

Authors:  H F Clemo; L Belardinelli
Journal:  Circ Res       Date:  1986-10       Impact factor: 17.367

7.  Diagnostic and therapeutic use of adenosine in patients with supraventricular tachyarrhythmias.

Authors:  J P diMarco; T D Sellers; B B Lerman; M L Greenberg; R M Berne; L Belardinelli
Journal:  J Am Coll Cardiol       Date:  1985-08       Impact factor: 24.094

8.  Isolated atrial myocytes: adenosine and acetylcholine increase potassium conductance.

Authors:  L Belardinelli; G Isenberg
Journal:  Am J Physiol       Date:  1983-05

9.  Inhibitory effects of KW-3902, a selective adenosine A1-receptor antagonist, on the adenosine-induced shortening of action potential duration in guinea pig atrial muscles.

Authors:  T Mori; T Moriyama; A Karasawa
Journal:  Jpn J Pharmacol       Date:  1993-10

10.  Therapeutic use of adenosine for terminating spontaneous paroxysmal supraventricular tachycardia.

Authors:  A Munoz; A Leenhardt; A Sassine; P Galley; P Puech
Journal:  Eur Heart J       Date:  1984-09       Impact factor: 29.983

View more
  5 in total

1.  Noninvasive diagnosis of cardiac arrhythmias using adenosine compounds.

Authors:  Bernard Belhassen
Journal:  Ann Noninvasive Electrocardiol       Date:  2002-01       Impact factor: 1.468

2.  Adenosine-Induced Atrial Fibrillation: Localized Reentrant Drivers in Lateral Right Atria due to Heterogeneous Expression of Adenosine A1 Receptors and GIRK4 Subunits in the Human Heart.

Authors:  Ning Li; Thomas A Csepe; Brian J Hansen; Lidiya V Sul; Anuradha Kalyanasundaram; Stanislav O Zakharkin; Jichao Zhao; Avirup Guha; David R Van Wagoner; Ahmet Kilic; Peter J Mohler; Paul M L Janssen; Brandon J Biesiadecki; John D Hummel; Raul Weiss; Vadim V Fedorov
Journal:  Circulation       Date:  2016-07-26       Impact factor: 29.690

Review 3.  Comprehensive evaluation of electrophysiological and 3D structural features of human atrial myocardium with insights on atrial fibrillation maintenance mechanisms.

Authors:  Aleksei V Mikhailov; Anuradha Kalyanasundaram; Ning Li; Shane S Scott; Esthela J Artiga; Megan M Subr; Jichao Zhao; Brian J Hansen; John D Hummel; Vadim V Fedorov
Journal:  J Mol Cell Cardiol       Date:  2020-10-29       Impact factor: 5.000

4.  Inhibition of Adenosine Pathway Alters Atrial Electrophysiology and Prevents Atrial Fibrillation.

Authors:  Luca Soattin; Anniek Frederike Lubberding; Bo Hjorth Bentzen; Torsten Christ; Thomas Jespersen
Journal:  Front Physiol       Date:  2020-06-12       Impact factor: 4.566

5.  Unmasking Arrhythmogenic Hubs of Reentry Driving Persistent Atrial Fibrillation for Patient-Specific Treatment.

Authors:  Brian J Hansen; Jichao Zhao; Katelynn M Helfrich; Ning Li; Alexander Iancau; Alexander M Zolotarev; Stanislav O Zakharkin; Anuradha Kalyanasundaram; Megan Subr; Nawshin Dastagir; Roshan Sharma; Esthela J Artiga; Nicholas Salgia; Mustafa M Houmsse; Omar Kahaly; Paul M L Janssen; Peter J Mohler; Nahush A Mokadam; Bryan A Whitson; Muhammad R Afzal; Orlando P Simonetti; John D Hummel; Vadim V Fedorov
Journal:  J Am Heart Assoc       Date:  2020-10-02       Impact factor: 5.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.